01 Adoption of Oral Antimicrobial Solutions in Livestock Adoption of oral antimicrobial solutions is influencing veterinary antibiotic formulation strategies, particularly in poultry and swine production. The European Medicines Agency reported that oral solutions had overtaken medicated feed premixes as the leading veterinary antimicrobial product form in the EU, reflecting changing treatment practices.
02 Preference for Long-Acting Injectable Antibiotic Formulations The animal antibiotics and antimicrobials market analysis highlights interest in long-acting injectable formulations for treating bacterial infections in livestock. These products reduce the frequency of antibiotic administration and support treatment compliance in large animal populations. Zoetis offers EXCEDE, a long-acting ceftiofur-based antibiotic for cattle.
01 Supply chain disruptions are expected to have a moderate impact on the animal antibiotics and antimicrobials market share due to shortages of active pharmaceutical ingredients, manufacturing delays, and higher transportation costs. The market is expected to experience a U-shaped recovery as pharmaceutical production and veterinary distribution networks gradually stabilize. Manufacturers dependent on imported ingredients may face longer recovery periods. The market is projected to grow at a CAGR of 4.03%. Supply constraints could reduce growth by an estimated 0.8 percentage points to 3.23%. Improved raw material availability and stable production capacity are expected to restore market growth to 4.03%.
01 The animal antibiotics and antimicrobials market forecasts continued investment in antimicrobial innovation, bacterial infection treatments, and antibiotic alternatives.
02 Key Investment and Funding Activities in Animal Antibiotics and Antimicrobials Market, 2025–2026 Company Value (USD) Details Nutrivert Inc. USD 2.375 Million In April 2026, Nutrivert secured initial Series A-2 funding to develop non-antibiotic livestock treatments and advance product safety and manufacturing studies. Phagos USD 30 Million In October 2025, Phagos raised Series A funding to advance bacteriophage therapies for bacterial infections in animals and expand its veterinary treatment platform.
01 Bacterial Disease Treatment Requirements and Adoption of Selective Dry Cow Therapy Drives Market Bacterial respiratory infections, mastitis, and enteric diseases are increasing the need for effective antibiotic treatments in livestock production. These infections reduce animal productivity and increase veterinary treatment expenses. For instance, bovine respiratory disease in feedlot cattle requires timely antibiotic treatment to prevent severe infections and production losses. The need to control bacterial disease transmission within commercial livestock herds is supporting demand for veterinary antimicrobials. The World Organization for Animal Health recognizes metaphylactic antimicrobial treatment for controlling infectious diseases under appropriate veterinary supervision. This treatment requirement supports demand for authorized oral and injectable antimicrobial formulations.
01 Strict Restrictions on Veterinary Antibiotic Usage and Antimicrobial Resistance Restrain Market Expansion Regulatory restrictions on routine antibiotic administration are limiting antimicrobial consumption in food-producing animals. Authorities are enforcing veterinary prescription requirements and restricting preventive antibiotic use without established clinical justification. The European Union has also established a target to reduce antimicrobial sales for farmed animals and aquaculture by 50% by 2030 compared with 2018.Emergence of antibiotic-resistant bacterial strains is reducing the effectiveness of certain veterinary antimicrobial treatments. Resistance can complicate the management of infections in poultry, cattle, and swine. Veterinarians may require additional susceptibility testing before selecting appropriate antibiotics.
01 Integration of Rapid Molecular Diagnostics and Development of Nanoparticle-based Antibiotic Delivery Systems Creates Growth Opportunities Advancements in polymerase chain reaction testing and rapid antimicrobial susceptibility technologies are creating growth opportunities for veterinary pharmaceutical manufacturers. These technologies help identify bacterial pathogens and select suitable antibiotics before treatment. Pharmaceutical companies can develop pathogen-specific antimicrobial formulations to address bacterial respiratory infections and mastitis in livestock.Innovations in nanotechnology are creating growth opportunities for veterinary drug manufacturers developing advanced antibiotic delivery systems. Nanoparticle-based drug carriers can improve antibiotic stability and enable sustained drug release at infection sites. These systems have potential applications in treating bovine mastitis and other bacterial infections.